EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Recruiting now · Not applicable
Conditions studied: Lung Cancer, EGFR Gene Mutation
In brief
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
Key facts
- Study ID
- NCT06716580
- Run by
- Dana-Farber Cancer Institute
- People needed
- 1000
- Starts
- 2025-04-01
- Expected to finish
- 2030-09-01
- Last updated by the study team
- 2026-07-15
Who can join
Age: 40 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute at Steward St. Elizabeth's — Brighton, Massachusetts, United States
- Dana-Farber Cancer Instiute Merrimack Valley — Methuen, Massachusetts, United States
- Dana-Farber Cancer Institute South Shore — South Weymouth, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.